胎盘、胎儿及母体心血管标志物在疑似或确诊子痫前期妇女中预测不良结局的作用
一项前瞻性预后准确性研究纳入126例疑似或确诊子痫前期孕妇,评估胎盘、胎儿及母体心血管标志物预测不良围产和母体结局的表现。sFlt-1/PlGF比值预测不良围产结局的AUC为0.87,表现最佳,但对不良母体结局预测能力差(AUC 0.69)。在sFlt-1/PlGF比值基础上增加心血管、胎儿或其他胎盘指标未改善预测。
要点
- sFlt-1/PlGF比值预测不良围产结局AUC 0.87,优于估计胎儿体重(AUC 0.81)。
- sFlt-1/PlGF比值对不良母体结局预测能力差,AUC 0.69。
- 在sFlt-1/PlGF比值上增加心血管或胎儿指标未改善预测。
核心结论
- sFlt-1/PlGF比值能较好地预测不良围产结局,但对不良母体结局预测能力差;在模型中加入心血管或胎儿指标似乎不能改善sFlt-1/PlGF比值的预后性能。
研究设计与样本
- 前瞻性预后准确性研究,纳入126例疑似(n=31)或确诊(n=95)子痫前期孕妇,中位孕周33.9周(四分位距30.9-36.3周)。
关键影像表现/征象
- 不良围产结局组较无不良围产结局组中位UtA-PI更高(1.3 vs 0.8;P < 0.001)。
- 不良围产结局组较无不良围产结局组中位眼动脉PSV比值更高(0.8 vs 0.7;P = 0.01)。
- 不良围产结局组较无不良围产结局组中位脐动脉PI百分位更高(82.0 vs 68.5;P < 0.01)。
- 不良围产结局组较无不良围产结局组中位估计胎儿体重百分位更低(4.0 vs 43.0;P < 0.001)。
- 不良围产结局组较无不良围产结局组中位腹围百分位更低(4.0 vs 63.0;P < 0.001)。
诊断标准与关键数值
- 预测不良围产结局:sFlt-1/PlGF比值AUC 0.87(95%CI 0.81-0.93),估计胎儿体重AUC 0.81(95%CI 0.73-0.89)。
- 预测不良母体结局:sFlt-1 AUC 0.69(95%CI 0.60-0.79),sFlt-1/PlGF比值AUC 0.69(95%CI 0.59-0.78)。
临床应用与阅片要点
- sFlt-1/PlGF比值可用于预测疑似或确诊子痫前期孕妇的不良围产结局。
- sFlt-1/PlGF比值对不良母体结局预测能力差,所有标志物预测不良母体结局表现均不佳。
- 在sFlt-1/PlGF比值基础上增加心血管、胎儿或其他胎盘指标未改善对不良母体或围产结局的预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the performance of placental, fetal and maternal cardiovascular markers in the prediction of adverse perinatal and maternal outcomes in women with suspected or confirmed pre-eclampsia.
METHODS: This was a prospective prognostic accuracy study of women with suspected or confirmed pre-eclampsia who underwent a series of investigations to measure maternal hemodynamic indices, mean arterial pressure, augmentation index, ophthalmic artery peak systolic velocity (PSV) ratio, uterine artery pulsatility index (UtA-PI), fetal biometric and Doppler parameters, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF). The performance of these markers, individually or in combination, in predicting adverse perinatal and maternal outcomes was then assessed using receiver-operating-characteristics (ROC)-curve analysis. Adverse maternal outcome was defined as one or more of severe hypertension, admission to the intensive care unit, eclampsia, placental abruption, HELLP syndrome, disseminated intravascular coagulation, platelets < 100 × 109 /L, creatinine > 90 μmol/L and alanine aminotransferase > 100 U/L. Adverse perinatal outcome was defined as one or more of preterm birth at or before 34 + 0 weeks, neonatal intensive care unit admission for > 48 h, respiratory distress syndrome, intraventricular hemorrhage, hypoxic ischemic encephalopathy, necrotizing enterocolitis, retinopathy of prematurity and confirmed fetal infection.
RESULTS: We recruited 126 women with suspected (n = 31) or confirmed (n = 95) pre-eclampsia at a median gestational age of 33.9 weeks (interquartile range, 30.9-36.3 weeks). Pregnancies with adverse perinatal outcome compared to those without had a higher median UtA-PI (1.3 vs 0.8; P < 0.001), ophthalmic artery PSV ratio (0.8 vs 0.7; P = 0.01) and umbilical artery PI percentile (82.0 vs 68.5; P < 0.01) and lower median estimated fetal weight percentile (4.0 vs 43.0; P < 0.001), abdominal circumference percentile (4.0 vs 63.0; P < 0.001), middle cerebral artery PI percentile (28.0 vs 58.5; P < 0.001) and cerebroplacental ratio percentile (18.0 vs 46.5; P < 0.001). Pregnancies with adverse perinatal outcome also had a higher median sFlt-1 (8208.0 pg/mL vs 4508.0 pg/mL; P < 0.001), lower PlGF (27.2 pg/mL vs 76.3 pg/mL; P < 0.001) and a higher sFlt-1/PlGF ratio (445.4 vs 74.4; P < 0.001). The best performing individual marker for predicting adverse perinatal outcome was the sFlt-1/PlGF ratio (area under the ROC curve (AUC), 0.87 (95% CI, 0.81-0.93)), followed by estimated fetal weight (AUC, 0.81 (95% CI, 0.73-0.89)). Women who experienced adverse maternal outcome had a higher median sFlt-1 level (7471.0 pg/mL vs 5131.0 pg/mL; P < 0.001) and sFlt-1/PlGF ratio (204.3 vs 93.3; P < 0.001) and a lower PlGF level (37.0 pg/mL vs 66.1 pg/mL; P = 0.01) and estimated fetal weight percentile (16.5 vs 37.0; P = 0.04). All markers performed poorly in predicting adverse maternal outcome, with sFlt-1 (AUC, 0.69 (95% CI, 0.60-0.79)) and sFlt-1/PlGF ratio (AUC, 0.69 (95% CI, 0.59-0.78)) demonstrating the best individual performance. The addition of cardiovascular, fetal or other placental indices to the sFlt-1/PlGF ratio did not improve the prediction of adverse maternal or perinatal outcomes.
CONCLUSIONS: The sFlt-1/PlGF ratio performs well in predicting adverse perinatal outcomes but is a poor predictor of adverse maternal outcomes in women with suspected or diagnosed pre-eclampsia. The addition of cardiovascular or fetal indices to the model is unlikely to improve the prognostic performance of the sFlt-1/PlGF ratio. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Reddy M, Palmer K, Rolnik DL, et al. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2022. PMID: 34985800. doi:10.1002/uog.24851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。